[{"address1": "1185 Avenue of the Americas", "address2": "3rd Floor", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "973 242 0005", "website": "https://www.synaptogen.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. The company was incorporated in 2012 and is headquartered in New York, New York.", "fullTimeEmployees": 5, "companyOfficers": [{"maxAge": 1, "name": "Dr. Alan J. Tuchman M.D., MBA(FAAN)", "age": 76, "title": "CEO & Director", "yearBorn": 1947, "fiscalYear": 2023, "totalPay": 303347, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Daniel L. Alkon M.D.", "age": 81, "title": "President, Chief Scientific Officer & Director", "yearBorn": 1942, "fiscalYear": 2023, "totalPay": 375000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Weinstein", "age": 63, "title": "CFO, Executive VP, Treasurer & Secretary", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 568918, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.14, "open": 3.12, "dayLow": 3.03, "dayHigh": 3.1748, "regularMarketPreviousClose": 3.14, "regularMarketOpen": 3.12, "regularMarketDayLow": 3.03, "regularMarketDayHigh": 3.1748, "beta": 1.44, "trailingPE": 0.29941577, "forwardPE": -0.36007026, "volume": 28152, "regularMarketVolume": 28152, "averageVolume": 29818, "averageVolume10days": 30530, "averageDailyVolume10Day": 30530, "marketCap": 4168500, "fiftyTwoWeekLow": 2.72, "fiftyTwoWeekHigh": 8.775, "fiftyDayAverage": 3.24744, "twoHundredDayAverage": 4.22064, "currency": "USD", "enterpriseValue": -23372822, "floatShares": 1286511, "sharesOutstanding": 1355610, "sharesShort": 17564, "sharesShortPriorMonth": 11261, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.012999999, "heldPercentInsiders": 0.0201, "heldPercentInstitutions": 0.00302, "shortRatio": 0.86, "shortPercentOfFloat": 0.013099999, "bookValue": 14.986, "priceToBook": 0.20519151, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -3445093, "trailingEps": 10.27, "forwardEps": -8.54, "enterpriseToEbitda": 3.423, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SNPX", "underlyingSymbol": "SNPX", "shortName": "Synaptogenix, Inc.", "longName": "Synaptogenix, Inc.", "firstTradeDateEpochUtc": 1607437800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d14ff140-0ac6-3af9-a386-f918dc6aa47f", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.075, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 27414324, "totalCashPerShare": 20.858, "ebitda": -6829012, "quickRatio": 2.931, "currentRatio": 2.975, "returnOnAssets": -0.13819, "returnOnEquity": -0.07495, "freeCashflow": 2585062, "operatingCashflow": -4922985, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-31"}]